MS & OTHER CNS DEMYELINATING DISEASES

DR. SALMAN ALJARALLAH, MBBS, FRCPC, ABNP

ASSISTANT PROFESSOR

CONSULTANT NEUROLOGIST

KSU, KKUH

Slides are Courtesy of Dr. Nuha Alkhawajah

MYELIN

Nuha Alkhawajah

MYELIN



DEMYELINATING DISEASES

Nuha Alkhawajah

ACQUIRED DEMYELINATING DISEASES

- Damage of th
- PNS & CNS.
- Inherited or a
- ***CNS:*** multiple ephalomyelitis (ADEM), neur MOSD).
- ***PNS:*** acute in thy (Guillain Barre syndrome), ch europathy (CIDP).



1-Multiple Sclerosis

Nuha Alkhawajah

INTRODUCTION

- MS is the most common chronic inflammatory, demyelinating and neurodegenerative disease of the CNS in young adults .
- The most common disorder causing disability in the young.
- It is a heterogeneous, multifactorial, immune-mediated disease that is caused by complex gene–environment interactions.

Nuha Alkhawajah

1. Filippi et al. NATURE REVIEWS DISEASE PRIMERS; NOV 8 2018; 4
2 . Murray. BMJ 2006 Mar 4; 332(7540): 525–527.

MS DISEASE COURSE

Nuha Alkhawajah

CLINICALLY ISOLATED SYNDROME (CIS)

- CIS is the first clinical episode that is suggestive of MS.
- characterized by:
  - Monophasic episode with symptoms and objective findings that reflect inflammatory demyelinating event in the CNS.
  - Acute or subacute, lasting for at least 24 hrs.
  - Occurs in the absence of fever or infection.
  - Resembles a typical MS relapse (attack) but occurs in a patient not known to have MS.

Thompson et al. Lancet Neurol 2018; 17: 162–73

RRMS



A purely RRMS is characterized by the ***absence*** of worsening neurological function outside of individual relapses

85%

https://www.mstrust.org.uk/about-ms/what-ms/types-ms
Tutuncu et al. Mult Scler. 2013 February ; 19(2): 188–198

RRMS



A purely RRMS is characterized by the ***absence*** of worsening neurological function outside of individual relapses

85%

https://www.mstrust.org.uk/about-ms/what-ms/types-ms
Tutuncu et al. Mult Scler. 2013 February ; 19(2): 188–198

PPMS



Irreversibly worsening neurological function, ***without*** preceding relapses

15%

https://www.mstrust.org.uk/about-ms/what-ms/types-ms
Tutuncu et al. Mult Scler. 2013 February ; 19(2): 188–198

SPMS



Worsening irreversible neurological function***, preceded*** by RRMS that cannot be explained purely by worsening associated with ongoing relapses

https://www.mstrust.org.uk/about-ms/what-ms/types-ms
Tutuncu et al. Mult Scler. 2013 February ; 19(2): 188–198

MS DISEASE COURSE

- The median time to conversion to SPMS is 21 years and median age at onset of 54 years. [1]

1.Koch et al. J. Neurol. Neurosurg. Psychiatry 81(9), 1039–1043 (2010).

MS EPIDEMIOLOGY

Nuha Alkhawajah

MS EPIDEMIOLOGY

- RRMS has an onset between 20-35 years.[1]
- PPMS begins at 40 years of age.[1]
- The median time to SPMS is 21 years and median age at onset is 54.[2]
- About one third of RRMS patients may never develop a progressive disease course[3].
- Up to 10% of patients experience their initial demyelinating event during childhood or adolescence.[1]

1.Filippi et al. NATURE REVIEWS DISEASE PRIMERS; NOV 8 2018; 4
2. Koch et al. J. Neurol. Neurosurg. Psychiatry 81(9), 1039–1043 (2010).
3.Tutuncu et al. Mult. Scler. 19(2), 188–198 (2013).

MS EPIDEMIOLOGY

- The risk is **0.1%** in the general population.
- The risk in people with an affected first-degree relative is **2-4%.**
- Concordance in monozygotic twins is **30-50%.**

Reich et al. N Engl J Med 2018;378:169-80.

MS EPIDEMIOLOGY

- MS is mainly found in individuals of European descent and is rare in Asian, black, Native Americans and Māori individuals.[1]
- Prevalence varies greatly, being highest in North America and Europe and lowest in Sub-Saharan Africa and East Asia.[2]
- The most striking epidemiological characteristic is the apparent uneven distribution of the disease across the world.[3]

1. Rosati, G. The prevalence of multiple sclerosis in the world: an update. *Neurol. Sci.* **22**, 117–139 (200).
2.MSIF.org HTTP://WW.MSIF.ORG/WP-CONTENT/UPLOADS/2014/09/ATLAS-OF-MS.PDF (2013)
3. Koch-Henriksen et al. ***Lancet Neurol* 2010; 9: 520–32**

PREVALENCE BY COUNTRY

Three factors are in effect:

1. population genetics
2. the interplay between genes and geographically determined physical environment.
3. and socioeconomic structure.

MSIF.org https://www.msif.org/wp- content/uploads/2014/09/Atlas- of-MS.pdf (2013)
Koch-Henriksen et al. ***Lancet Neurol* 2010; 9: 520–32**

MS EPIDEMIOLOGY

- The prevalence of MS has increased since the 1950s, especially in women.
- The female to male ratio of MS, has increased to ~3:1.
- This suggests a possible role of environmental risk factors:
  - Occupation.
  - Increased cigarette smoking.
  - Obesity.
  - Birth control and childbirth.

Filippi et al. NATURE REVIEWS DISEASE PRIMERS; NOV 8 2018; 4

MS EPIDEMIOLOGY

- The life expectancy of patients is reduced by **7–14 years**.[1]
- Patients older at onset or with PPMS have shorter survival.[2]
- MS is the main cause of death in more than 50% of patients.[2]
- Suicide is particularly substantially increased.[2]

1.Filippi et al. NATURE REVIEWS DISEASE PRIMERS; NOV 8 2018.
2-Scalfari et al. Neurology 2013;81:184–192

MS RISK FACTORS

Nuha Alkhawajah

ENVIRONMENTAL RISK FACTORS

1. ***EBV Infection:***
   - History of infectious mononucleosis (EBV) is associated with higher risk of MS.
   - Antibodies to EBV were higher in people who developed MS than in control samples.

2. ***Vitamin D:***
   - Sunlight may be protective (ultraviolet radiation or vitamin D).
   - Sun exposure & serum vitamin D are inversely related to risk/prevalence of MS.
   - Vitamin D levels are inversely related to MS disease activity.

CONT.

3. ***Smoking:***

- a higher risk of MS in ever-smok
- smoking may also be a risk f

leptin increases the proliferation of auto-aggressive cells responsible for myelin damage.

4. ***Obesity:***

- in adolescence or early adulthood is associated with increased risk for MS.

MS PATHOLOGY

Nuha Alkhawajah

PATHOLOGY & PATHOGENESIS



Reich et al. N Engl J Med 2018;378:169-80.
PICs from very well mind and WIKIPEDIA



Nuha Alkhawajah

Reich et al. NEngl J Med 2018;378:169-80.

PATHOLOGY & PATHOGENESIS

- Lesions are m e matter.







bility

Fillipi et al . Nature rev dis primers. 2018 Nov 8;4(1):43
First Pic from Wikipedia

MS Symptoms

Nuha Alkhawajah

OPTIC NEURITIS

- Blurred vision.
- Pain exacerbated by ey
- Reduced perception of
- Flashes of light on mov
- Enlarged blind spot.

BRAIN STEM RELATED MS SYMPTOMS







CEREBELLUM RELATED MS SYMPTOMS

A visual disturbance in which the object in the visual field appears to oscillate

- Oscillopsia.
- Dysarthria.
- Imbalance.



Pic from protokinetics.com

BRAIN AND SPINAL CORD MS SYMPTOMS

- Weakness (monoparesis, paraparesis, qua
- Sensory loss/numbness/pain
- Sphicteric dysfunction.
- Lhermitte's sign??
- Cognitive dysfunction: memory, concentration, processing speed.



TRANSVERSE MYELITIS

- A general term that indicates inflammation of the spinal cord.
- Could be caused by MS, infections, connective tissue diseases…..
- Spinal cord related motor, sensory &/or autonomic dysfunction.
- Sensory level.
- Unilateral or bilateral.

UHTHOFF'S PHENOMENA

- Neurological dysfunction.
- Stereotyped.
- Less than 24 h.
- Reversible.
- Related to fluctuations in axonal conduction properties due to increasing body temperature.

DIAGNOSING MS

Nuha Alkhawajah

DIAGNOSING MS

History & Exam

Nuha Alkhawajah

2017 MCDONALD CRITERIA

	Number of lesions with objective clinical evidence	Additional data needed for a diagnosis of multiple sclerosis
≥2 clinical attacks	≥2	None*
≥2 clinical attacks	1 (as well as clear-cut historical evidence of a previous attack involving a lesion in a distinct anatomical location†)	None*
≥2 clinical attacks	1	Dissemination in space demonstrated by an additional clinical attack implicating a different CNS site or by MRI‡
1 clinical attack	≥2	Dissemination in time demonstrated by an additional clinical attack or by MRI§ OR demonstration of CSF-specific oligoclonal bands¶
1 clinical attack	1	Dissemination in space demonstrated by an additional clinical attack implicating a different CNS site or by MRI‡ AND Dissemination in time demonstrated by an additional clinical attack or by MRI§ OR demonstration of CSF-specific oligoclonal bands¶

Lancet Neurol 2018; 17: 162–73

DIAGNOSIS OF MS

- Imaging: MRI of the brain and spinal cord









Fillipi et al. Lancet Neurology 2016
Chen et al. Multiple Sclerosis 2010

MS DIAGNOSIS

- Lumbar punctur



Image from Wikipedia



Pic from wikipedia



MS TREATMENT

A. ***Acute treatment of relapses.***

A. ***Disease Modifying treatments.***

MS TREATMENT

A. ***Acute treatment of relapses***

- Steroids (IV Methylprednisone) for 3-5 days
- plasma exchange.

MS TREATMENT

B. Disease Modifying treatments

- Reduction of number of relapses per year.
- Reduction of number of new MRI lesions.
- Prolongation of time to development of secondary progressive disease.
- Reduction of long term disability.

MS TREATMENT

- 1980's: Steroids for relapses only.
- 1990's: Disease modifying therapies (interferons & glatiramer acetate).
- 2000's: Mitoxantrone for aggressive MS and Natalizumab.
- 2010's: Oral medications now available (Fingolimod, teriflunomide, dimethylfumarate..).
- 2017 first approved treatment for PPMS: Ocrelizumab.

2-NEUROMYELITIS OPTICA SPECTRUM DISORDER

Nuha Alkhawajah

2-NEUROMYELITIS OPTICA SPECTRUM DISORDER

- Also known as Devic's disease.
- More common in females (**9:1**).
- Mean ***age*** is 10 years later than MS.
- More common in ***Asian and African*** populations.
- Affects ***mainly*** the optic nerves and the spinal cord.
- More severe attacks than in MS.
- Usually negative OCB in the CSF.
- More likely to have pleocytosis in the CSF.



NMO PATHOLOGY

- Astrocytopathy.
- Targets aquaporine 4 (a water channel) rich areas (aquaporine 4 abd in 70%).
- Vasculocentric and rosette pattern deposition of immunoglobulin and complement.

NMO TREATMENT

A. *Acute treatment of relapses*

- steroids or plasma exchange.

MS treatments may worsen NMO

B. *Disease Modifying treatments*

- chronic immunosuppression with azathioprine, Rituximab, mycophenolate mofetil….

Dr. Nuha Alkhawajah

3- Acute Disseminated Encephalomyelitis

Nuha Alkhawajah

ADEM

- CNS inflammatory demyelinating disease.
- Frequently ***preceded by*** vaccination or infection.
- More common in ***children.***
- ***Equal*** males to females ratio.
- Affects ***all*** ethnicities.
- Usually a ***monophasic*** illness (no relapses).

ADEM

PTHOLOGY:

- Wide spread white and gray matter peri-venous "sleeves" of inflammation and demyelination.

- Axons are relatively spared.

ADEM

- ***SYMPTOMS:***
  - Encephalopathy (lethargy, stupor, coma).
  - Multifocal neurological deficit (visual symptoms, ataxia, TM..).
  - May fluctuates over a 3 months period.

Table III

Comparison of Clinical Characteristics in ADEM and MS

Features	ADEM	MS
Antecedent events	Infections or vaccination	No recognized antecedent infections or vaccination
Clinical characteristics	Meningism, stupor, focal signs	Focal signs
Course	Non progressive, monophasic	Relapsing and remitting or progressive
Recovery	Recovery is rapid and often complete	Recovery variable, may be rapid and complete

ADEM TREATMENT

- Acute treatment: Steroids, plasma exchange and intravenous immunoglobulins.

- Disease modifying treatments: ???

SUMMARY

- ***MS:***
  - A demyelinating disease.
  - Can affect any part of the CNS.
  - A disease of young adults.
  - More common in females.
  - RR course is the most common initial course.

SUMMARY

- ***NMOSD:***
  - A demyelinating disease.
  - Can affect any part of the CNS but mainly optic nerve and spinal cord.
  - Older group in comparison to MS.
  - More in females.
  - Relapsing course.

SUMMARY

- ***ADEM:***
  - Acute inflammatory demyelinating disease.
  - Monophasic.
  - More common in children.
  - Follows infection or vaccination.
  - Encephalopathy is a pre-requisite for the diagnosis in children.

MS VS NMO VS ADEM

	MS	NMO	ADEM
AGE	30	40	5-8
GENDER	females 3:1	females 9:1	Equal or males 1-1.3:1
ETHNICITY	NA and Europe	Asia	all
SYMPTOMS	CNS	CNS (ON AND TM)	CNS
COURSE	RR/progressive	Relapsing	Monophasic
TRANSVERSE MYELITIS	Yes <3 v. segments	Yes > 3 v. segment	Yes <3 v. segments
ACUTE TREATMENT	Streoids and PLEX	Streoids and PLEX	Streoids and PLEX
Disease Modifying treatment	Yes	Yes	No need

Thank you